35: A phase 1/2 trial investigating ivosidenib plus nivolumab and ipilimumab in patients with previously treated mIDH1 CCA
Robin Kate Kelley, James M Cleary, Vaibhav Sahai, Marina Baretti, John Bridgewater, Clement Daniel, Camelia Gliser, Ghassan K Abou-Alfa · 2026
Read 35: A phase 1/2 trial investigating ivosidenib plus nivolumab and ipilimumab in patients with previously treated mIDH1 CCA by Robin Kate Kelley, James M Cleary, Vaibhav Sahai, Marina Baretti, John Bridgewater, Clement Daniel, Camelia Gliser, Ghassan K Abou-Alfa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13287888.txt.
Description
Robin Kate Kelley and co-authors report a halted drug combination trial in bile duct cancer, published in 2026. The cancer carried a mutation in the IDH1 gene, which the drug ivosidenib targets. Two immune therapy drugs, nivolumab and ipilimumab, were added in hope of a stronger joint effect. The phase 1/2 study enrolled patients whose cancer had grown after one or two earlier treatments.
Only seven patients entered the safety lead-in phase before problems stopped the trial. Every patient developed immune-related side effects, most often rashes that appeared within about twelve days. Lowering the ivosidenib dose did not prevent the reactions in the next three patients. Several rashes were serious, and no patient showed a clear tumor response on scans. The sponsors closed recruitment, and other studies are testing different partners for ivosidenib instead.
Catalog record
| CREATOR | Robin Kate Kelley, James M Cleary, Vaibhav Sahai, Marina Baretti, John Bridgewater, Clement Daniel, Camelia Gliser, Ghassan K Abou-Alfa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |